Mobile website
Archive > Volume 29 Issue 3 > 2022,29(3):225-229. DOI:10.3872/j.issn.1007-385X.2022.03.009 Prev Next
Clinical Research
Efficacy and safety of anti-PD-1 antibody combined with chemotherapy and anti-angiogenic drugs in advanced melanoma
- Article
- Figures
- Metrics
- Preview PDF
- Reference
- Related
- Cited by
- Materials
Abstract:
Objective: To investigate the efficacy and safety of anti-PD-1 antibody combined with chemotherapy and anti-angiogenic drugs in the treatment of advanced melanoma. Methods: The clinical data of 14 patients (6 males and 8 females) with unresectable advanced melanoma who received anti-PD-1 antibody combined with chemotherapy (temozolomide±cisplatin, albumin bound paclitaxel) and anti-angiogenic drug (bevacizumab) in Peking University Cancer Hospital from April 2020 to June 2021 were collected. The primary endpoint was the progression-free survival (PFS), and the secondary endpoints were objective response rate (ORR), disease control rate (DCR), overall survival (OS) and safety data (CTCAE 5.0). Results: All of the 14 patients with advanced melanoma were included in the survival analysis. The median follow-up time was 5.50 months (95% CI: 0-13.12 months). The median PFS was 7.43 months (95% CI: 3.07-11.79 months), and the median OS was 13.50 months (95% CI: 5.19-21.81 months). The median onset time was 1.5 months. The ORR was 28.6% (all the 4 patients were in partial remission) and the DCR was 85.7%. The adverse events were almost grade 1-2. Conclusion: Chemotherapy combined with anti-PD-1 antibody and anti-angiogenic drug showed certain efficacy and safety in patients with advanced melanoma, which might provide new ideas for the combined treatment of advanced melanoma.
Keywords:
Project Supported:
Clc Number:
R739.5; R730.5; R730.7
